NPM1mut can be targeted directly or through the pathways it interacts with (reviewed in [45]) using drugs such as Venetoclax, a selective Bcl-2 inhibitor which when used in combination with 5′-azacytidine has shown anti-leukemic activity in 60–70% of AML patients [46]. The gene discussed is BCL2; the disease is acute myeloid leukemia.